WO2008070268A3 - Pharmaceutical compositions - Google Patents

Pharmaceutical compositions Download PDF

Info

Publication number
WO2008070268A3
WO2008070268A3 PCT/US2007/080831 US2007080831W WO2008070268A3 WO 2008070268 A3 WO2008070268 A3 WO 2008070268A3 US 2007080831 W US2007080831 W US 2007080831W WO 2008070268 A3 WO2008070268 A3 WO 2008070268A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical compositions
analgesic
treat
eliminate
subject
Prior art date
Application number
PCT/US2007/080831
Other languages
French (fr)
Other versions
WO2008070268A2 (en
Inventor
Paul Bosse
Original Assignee
Charleston Lab Inc
Paul Bosse
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to SI200731562T priority Critical patent/SI2124556T1/en
Priority to US12/444,521 priority patent/US8653066B2/en
Priority to EP07871139.7A priority patent/EP2124556B1/en
Priority to JP2009531645A priority patent/JP2010522135A/en
Priority to CA2665841A priority patent/CA2665841C/en
Priority to PL07871139T priority patent/PL2124556T3/en
Priority to DK07871139.7T priority patent/DK2124556T3/en
Priority to ES07871139.7T priority patent/ES2524556T3/en
Application filed by Charleston Lab Inc, Paul Bosse filed Critical Charleston Lab Inc
Publication of WO2008070268A2 publication Critical patent/WO2008070268A2/en
Publication of WO2008070268A3 publication Critical patent/WO2008070268A3/en
Priority to HK10105451.9A priority patent/HK1138732A1/en
Priority to US14/099,432 priority patent/US20140134248A1/en
Priority to US14/748,605 priority patent/US9402813B2/en
Priority to US14/748,614 priority patent/US9393207B2/en
Priority to US14/748,609 priority patent/US9399022B2/en
Priority to US14/748,617 priority patent/US20150328212A1/en
Priority to US14/748,613 priority patent/US20150328210A1/en
Priority to US14/748,621 priority patent/US9427407B2/en
Priority to US15/263,235 priority patent/US20160375014A1/en
Priority to US15/263,230 priority patent/US20160375013A1/en
Priority to US15/679,460 priority patent/US20170340627A1/en
Priority to US16/425,401 priority patent/US20200054625A1/en
Priority to US17/229,479 priority patent/US20220062276A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

Pharmaceutical compositions are provided which comprise effective amounts of analgesic to treat a subject, including to reduce or eliminate an adverse effect associated with the analgesic.
PCT/US2007/080831 2006-10-09 2007-10-09 Pharmaceutical compositions WO2008070268A2 (en)

Priority Applications (21)

Application Number Priority Date Filing Date Title
US12/444,521 US8653066B2 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
EP07871139.7A EP2124556B1 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
JP2009531645A JP2010522135A (en) 2006-10-09 2007-10-09 Pharmaceutical composition
CA2665841A CA2665841C (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
PL07871139T PL2124556T3 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
SI200731562T SI2124556T1 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
DK07871139.7T DK2124556T3 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
ES07871139.7T ES2524556T3 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
HK10105451.9A HK1138732A1 (en) 2006-10-09 2010-06-02 Pharmaceutical compositions
US14/099,432 US20140134248A1 (en) 2006-10-09 2013-12-06 Pharmaceutical compositions
US14/748,621 US9427407B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,605 US9402813B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,613 US20150328210A1 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,614 US9393207B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,609 US9399022B2 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US14/748,617 US20150328212A1 (en) 2006-10-09 2015-06-24 Pharmaceutical compositions
US15/263,235 US20160375014A1 (en) 2006-10-09 2016-09-12 Pharmaceutical compositions
US15/263,230 US20160375013A1 (en) 2006-10-09 2016-09-12 Pharmaceutical compositions
US15/679,460 US20170340627A1 (en) 2006-10-09 2017-08-17 Pharmaceutical compositions
US16/425,401 US20200054625A1 (en) 2006-10-09 2019-05-29 Pharmaceutical Compositions
US17/229,479 US20220062276A1 (en) 2006-10-09 2021-04-13 Pharmaceutical compositions

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US85045106P 2006-10-09 2006-10-09
US60/850,451 2006-10-09
US95256307P 2007-04-03 2007-04-03
US60/952,563 2007-04-03
US94837507P 2007-07-06 2007-07-06
US60/948,375 2007-07-06

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/444,521 A-371-Of-International US8653066B2 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions
US14/099,432 Continuation US20140134248A1 (en) 2006-10-09 2013-12-06 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
WO2008070268A2 WO2008070268A2 (en) 2008-06-12
WO2008070268A3 true WO2008070268A3 (en) 2008-11-27

Family

ID=39492908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/080831 WO2008070268A2 (en) 2006-10-09 2007-10-09 Pharmaceutical compositions

Country Status (3)

Country Link
CA (1) CA2918576C (en)
PT (1) PT2124556E (en)
WO (1) WO2008070268A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2184276A1 (en) 2008-11-07 2010-05-12 Universite Paul Cezanne Aix-Marseille Iii Process to prepare new substituted 1H-Benzo(d) imidazol-2(3h)-Ones, New intermediates and their use as bace 1 inhibitors
WO2010065930A1 (en) * 2008-12-04 2010-06-10 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for treating or preventing narcotic withdrawal symptoms
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015157509A1 (en) * 2014-04-10 2015-10-15 The Trustees Of The University Of Pennsylvania Compositions and methods for treating opioid receptor associated diseases
EP3129028A4 (en) * 2014-04-10 2017-12-06 Charleston Laboratories, Inc. Pharmaceutical compositions
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
AU2015336065A1 (en) 2014-10-20 2017-05-04 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
WO2017066488A1 (en) * 2015-10-13 2017-04-20 Charleston Laboratories, Inc. Treating pain using a composition comprising an opioid and an antiemetic
JP2019507181A (en) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド Pharmaceutical composition
US20170354603A1 (en) * 2016-06-10 2017-12-14 Charleston Laboratories, Inc. Pharmaceutical compositions
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn
WO2022015784A1 (en) 2020-07-15 2022-01-20 Schabar Research Associates Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5055461A (en) * 1989-02-15 1991-10-08 Richardson-Vicks Inc. Anesthetic oral compositions and methods of use
US5738874A (en) * 1992-09-24 1998-04-14 Jagotec Ag Pharmaceutical tablet capable of liberating one or more drugs at different release rates

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2124556A4 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8653066B2 (en) 2006-10-09 2014-02-18 Charleston Laboratories, Inc. Pharmaceutical compositions
US9393207B2 (en) 2006-10-09 2016-07-19 Locl Pharma, Inc. Pharmaceutical compositions
US9399022B2 (en) 2006-10-09 2016-07-26 Locl Pharma, Inc. Pharmaceutical compositions
US9402813B2 (en) 2006-10-09 2016-08-02 Locl Pharma, Inc. Pharmaceutical compositions
US9427407B2 (en) 2006-10-09 2016-08-30 Locl Pharma, Inc. Pharmaceutical compositions
US9198867B2 (en) 2008-01-09 2015-12-01 Charleston Laboratories, Inc. Pharmaceutical compositions
US9226901B2 (en) 2008-01-09 2016-01-05 Locl Pharma, Inc. Pharmaceutical compositions
US9387177B2 (en) 2008-01-09 2016-07-12 Locl Pharma, Inc. Pharmaceutical compositions
US9498444B2 (en) 2008-01-09 2016-11-22 Locl Pharma, Inc. Pharmaceutical compositions
US8728522B2 (en) 2009-07-08 2014-05-20 Charleston Laboratories, Inc. Pharmaceutical compositions for treating or preventing pain
US9433625B2 (en) 2009-07-08 2016-09-06 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain
US9526704B2 (en) 2009-07-08 2016-12-27 Locl Pharma, Inc. Pharmaceutical compositions for treating or preventing pain

Also Published As

Publication number Publication date
WO2008070268A2 (en) 2008-06-12
PT2124556E (en) 2014-12-03
CA2918576C (en) 2019-01-08
CA2918576A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
WO2008070268A3 (en) Pharmaceutical compositions
WO2009089494A3 (en) Pharmaceutical compositions
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012061290A3 (en) Pesticidal compositions and processes related thereto
WO2007109192A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2009152356A3 (en) Compounds and compositions useful for the treatment of malaria
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
WO2007109172A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007093627A3 (en) Biocidal composition
WO2007109154A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109160A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2008115281A3 (en) Compounds for treating viral infections
WO2010132882A8 (en) Sublingual dexmedetomidine compositions and methods of use thereof
WO2007109182A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2007109201A3 (en) Bicycloheteroaryl compounds as p2x7 modulators and uses thereof
WO2010049454A3 (en) Antimicrobial composition from copepods
TW200942524A (en) Novel aminomethyl benzene derivatives
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2008129501A3 (en) Pharmaceutical compositions of duloxetine
WO2010014258A3 (en) Conjugates having a releasable linkage
WO2007144057A3 (en) Antimicrobial carbon
WO2010062506A3 (en) Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2011088160A3 (en) Novel cyp17 inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07871139

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007871139

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009531645

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2665841

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12444521

Country of ref document: US